Metrics as of 10/16/2026, 02:20 PM (Berlin time), refresh in progress.
Silence Therapeutics Stock
Silence Therapeutics plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Iain Gladstone Ross
- Employees
- 88
- Market cap
- $442 M
- IPO
- 08/09/2020
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is…
Silence Therapeutics stock: price history
1D
+4.1%
1W
-1.8%
1M
-25.0%
6M
+23.0%
YTD
+53.8%
1Y
+46.6%
2Y
-48.9%
5Y
-57.1%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~28% stronger price swings than usual
Silence Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 29/09/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
Silence Therapeutics plc is a UK-based biotechnology company specializing in the development of RNA therapeutics. The company leverages a proprietary mRNAi GalNAc oligonucleotide discovery platform to selectively modulate genes in the liver and treat diseases such as cardiovascular disorders and rare metabolic conditions. Current revenue is generated entirely from research collaboration agreements with partners including AstraZeneca PLC, Mallinckrodt Pharma IP Trading DAC, and Hansoh Pharmaceutical Group Company Limited. Several drug candidates including SLN360 and SLN124 are currently in Phase I clinical development.
- Revenue model
- Licensing
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Efficient scale
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
AstraZeneca PLCDescriptionAsk the agents about Silence Therapeutics
Analyst assessment of Silence Therapeutics
PRICE TARGET LOW
US$49.00
CONSENSUS
US$57.00
MEDIAN
US$55.00
PRICE TARGET HIGH
US$67.00
0
STRONG BUY
4
BUY
0
HOLD
1
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 11/08/2026
Silence Therapeutics stock metrics
P/E
-2.45
P/B
3.83
EV/EBITDA
-6.13
RETURN ON EQUITY
-31.9%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
79.7%
FLOAT SHARES
37,668,546
AVG. DAILY VOLUME (30D)
1,018,473
Attention
Price since yesterday: +4.1%
Search (Google Trends)
Institutional holders
Comparable stocks
Frequently asked questions about Silence Therapeutics stock
What does Silence Therapeutics do?
Silence Therapeutics plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Iain Gladstone Ross, the company employs around 88 people.
The IPO was on 08/09/2020; the stock trades on NASDAQ under the ticker SLN.
What do analysts say about Silence Therapeutics stock?
5 analysts rate the stock, the consensus is Buy (as of 11/08/2026).
The average price target is US$57.00, ranging from US$49.00 to US$67.00, with a median of US$55.00.
This is an external assessment, not a statement by Market Jury.
When does Silence Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 28% stronger than usual.
Does Silence Therapeutics pay a dividend?
No, Silence Therapeutics currently does not pay a dividend.
Which stocks are comparable to Silence Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Silence Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Silence Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.